Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment - PubMed
21 hours ago
- #tumor microenvironment
- #Treg cell reprogramming
- #CD40 agonist
- Agonistic anti-CD40 antibody treatment reduces regulatory T cells in pancreatic ductal adenocarcinoma.
- The reduction occurs via CD40-activated dendritic cells and cytokines like IL-12 and IFN-γ.
- Regulatory T cells lose Foxp3 expression, acquiring Th1-like features (e.g., Tbet+ IFN-γ+).
- Treatment reorganizes the tumor microenvironment, relocating Treg and ExTreg cells to the periphery.
- ExTreg cells show high antigen-driven activation and anti-tumor effector capacity.